/Bristol-Myers%20Squibb%20Co_%20logo%20on%20building-by%20tatu%20Campelo%20via%20iStock.jpg)
With a market cap of $102.7 billion, Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines for serious diseases in oncology, immunology, cardiovascular, and other key therapeutic areas. Backed by a strong portfolio of blockbuster drugs like Opdivo and Eliquis, the company continues to expand its impact through strategic acquisitions, advanced research, and a focus on high-need patient populations.
BMY is set to unveil its fiscal Q1 2025 earnings results before the market opens on Thursday, Apr. 24. Ahead of this event, analysts expect the Princeton, New Jersey-based company to report an adjusted EPS of $1.56 per share, up 135.5% from a loss of $4.40 per share in the year-ago quarter. It has surpassed Wall Street's bottom-line estimates in the past four quarters. In Q4 2024, BMY exceeded the consensus adjusted EPS estimate by a margin of 14.4%.